Mumbai, Nov. 16 -- Glenmark Pharmaceuticals Inc., USA (Glenmark), today announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an Authorized Generic version of INLYTA(R)1 (axitinib) tablets.

According to IQVIA(R) sales data for the 12-month period ending September 2026, U.S. annual sales of INLYTA(R) Tablets were approximately $538.4 million

Published by HT Digital Content Services with permission from Capital Market....